PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Artcle 36 and Rule 70)

	(PC1 Article 36 and Rule 70)	To the second se
Applicant's or agent's file reference 4FPO-08-34	FOR FURTHER ACTION	See Form PCT/IPEA/416
DOMEST Z DAGG A GOGGGGG	nternational filing date(day/month/year)	Priority date (day/month/year)
	14 SEPTEMBER 2004 (14.09.200	4) 15 SEPTEMBER 2003 (15.09.2003)
nternational Patent Classification (IPC) of	r national classification and IPC	
A61K 36/254(2006.01)i, A23L	1/29(2006.01)i, A61P 15/10(200	06.01)i
	,,, ====	
Applicant KOREA RESEARCH INSTITU	TE OF BIOSCIENCE AND BIO	TECHNOLOGY et al
This report is the international prelin Authority under Article 35 and trans	minary examination report, established by the smitted to the applicant according to Article	nis International Preliminary Examining 36.
2. This REPORT consists of a total of	5 sheets, including this cover	er sheet.
This report is also accompanied by	ANNEXES, comprising:	•
	the International Bureau) a total of	
and/or sheets contain	ption, claims and/or drawings which have t ning rectifications authorized by this Autho	neen amended and are the basis for this report rity (see Rule 70.16 and Section 607 of the
Administrative Instr	ructions).	
sheets which supers	ede earlier sheets, but which this Authority	considers contain an amendment that goes
Supplemental Box.	re in the international application as filed, as	s indicated in item 4 of Box No. I and the
b. (sent to the International B	ureau only) a total of (indicate type and nur	mber of electronic carrier(s)),
containing a sequence listing	ng and/or tables related thereto, in electronic isting (see Section 802 of the Administrative)	form only, as indicated in the Supplemental
	same (see section 602 of the Administrative	e nisu actions).
4. This report contains indications relat	ing to the following items:	
Box No. I Basis of the rep		
Box No. II Priority		
Box No. III Non-establishr	ment of opinion with regard to novelty, inve	entive step and industrial applicability
Box No. IV Lack of unity		терительный другий в принципу
Box No. V Reasoned state citations and ex	ement under Article 35(2) with regard to no xplanations supporting such statement	velty, inventive step or industrial applicability;
Box No. VI Certain docum	ients cited	
Box No. VII Certain defects	in the international application	
Box No. VIII Certain observe	ations on the international application	
ate of submission of the demand	Date of completion	of this report
26 APRIL 2005 (26.0	03 JANUA	ARY 2006 (03.01.2006)
ame and mailing address of the IPEA/KR	Authorized officer	
Korean Intellectual Property O 920 Dunsan-dong, Seo-gu, Dae Republic of Korea	ffice	
csimile No. 82-42-472-7140	Telephone No. 92	42 491 5/27

International application No.
PCT/KR2004/002338

Box No	. I Basis of the report
1. W	ith regard to the language, this report is based on the international application in the language in which it was filed, unless nerwise indicated under this item. This report is based on translations from the original language into the following language
to th	n regard to the elements of the international application, this report is based on (replacement sheets which have been furnished are receiving Office in response to an invitation under Article 14 are referred to in this reort as "originally filed" and are not exed to this report): the international application as originally filed/furnished
	the description: pages as originally filed/furnished pages* as originally filed/furnished
	the claims: pages
	pages* as amended (together with any statment) under Article 19 pages* received by this Authority on pages* received by this Authority on
لـا	the drawings: pages
3.	the sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing.
· .	The amendments have resulted in the cancellation of: the description, pages the claims, Nos. the drawings, sheets the sequence listing (specify): any table(s) related to sequence listing (specify):
4.	This report has been established as if (some of) the amendments annexed to this report and listed below had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)). the description, pages the claims, Nos. the drawings, sheets the sequence listing (specify): any table(s) related to sequence listing (specify):
* If item	4 applies, some or all of those sheets may be marked "superseded."

International application No.
PCT/KR2004/002338

В	Box No. IV Lack of unity of invention				
1.		In response to the invitation to restrict or pay additional fees the applicant has, within the applicable time limit: restricted the claims paid additional fees paid additional fees under protest and, where applicable, the protest fee paid additional fees under protest but the applicable protest fee was not paid neither restricted nor paid additional fees.			
2.		This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.			
3.	This	Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is : complied with. not complied with for the following reasons:			
		Claim 7 is directed to a health food, and claim 8 is directed to a pharmaceutical composition.			
		Although claims 7 and 8 are relevant to the composition comprising the same active ingredient, there is no technical relationship among a pharmaceutical composition and health food.			
		Hence, the application contains the following separate groups of inventions not so linked as to form a single general inventive concept (PCT Rule 13.1):			
		i) Claims 1-7 ii) Claims 1-6 and 8			
4. (∑ a	quently, this report has been established in respect of the following parts of the international application:			
	t ¹	the parts relating to claims Nos.			

International application No.

PCT/KR2004/002338

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Statement .			
Novelty (N)	Claims	3	YES
•	Claims	1, 2, 4-8	NO
Inventive step (IS)	Claims	3	YES
	Claims	1, 2, 4-8	NO
Industrial applicability (IA)	Claims	1-8	YES
	Claims		NO

2. Citations and explanations (Rule 70.7)

The present invention relates to a composition for the improvement or treatment of erectile dysfunction, comprising an alcohol extract of ogalpi(= Acanthopanacis Cortex) as an active ingredient.

The following document has been considered for the purpose of this report:

 $D1 = JP \ 2000 - 319191 \ A \ (21.11.2000)$

1) Novelty & Inventive step

Claims 1, 2 and 4-8 relate to an alcohol extract of ogalpi such as *Acanthopanax* senticosus, and a composition comprising the same as an active ingredient for the improvement or treatment of erectile dysfunction.

The cited document D1 states that an alcohol extract of *Acanthopanax senticosus* has the cGMP-phosphodiesterase inhibitory activity and is useful for preventing and treating erectile dysfunction.

Therefore, the subject-matter of claims 1, 2 and 4-8 is neither novel nor inventive (PCT Article 33(2) and 33(3)).

(Continued on Supplemental Sheet.)

International application No.

PCT/KR2004/002338

Supp	lemental	Box
------	----------	-----

In case the space in any of the preceding boxes is not sufficient. Continuation of:

Box V.

On the other hand, claim 3 relates to an extract of *Acanthopanax divaricatus* var. *albeofructus* for improving erectile dysfunction.

Even though D1 are relevant to the present invention, it does not describe the use of *Acanthopanax divaricatus* var. *albeofructus* extract for improving or treating erectile dysfunction.

As a consequence, claim 3 meets the criteria set out in PCT Article 33(2) and 33(3).

2) Industrial applicability.

Claims 1-8 meet the criteria set out in PCT Article 33(4).